CA2369457A1 - Ocular treatment using cyclosporin-a derivatives - Google Patents
Ocular treatment using cyclosporin-a derivatives Download PDFInfo
- Publication number
- CA2369457A1 CA2369457A1 CA002369457A CA2369457A CA2369457A1 CA 2369457 A1 CA2369457 A1 CA 2369457A1 CA 002369457 A CA002369457 A CA 002369457A CA 2369457 A CA2369457 A CA 2369457A CA 2369457 A1 CA2369457 A1 CA 2369457A1
- Authority
- CA
- Canada
- Prior art keywords
- nr1r2
- pharmaceutically acceptable
- acceptable excipient
- alkyl
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Abstract
A method of treating a disorder in an eye, for example, an aqueous deficient dry eye state, phacoanaphylactic endophthalmitis, or uveitis, is provided. The method generally includes administering a therapeutically effective amount of a certain cyclosporin A derivative topically to the affected eye. The derivative may be administered as a solution, suspension or ointment in a pharmaceutically acceptable excipient.
Claims (18)
1. A method for the treatment of an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, said method comprising administering, topically to the eye, a therapeutically effective amount of a cyclosporin A derivative selected from the group consisting of compounds represented by the general formulas:
wherein Me is methyl; Alk is 2-6C alkylene or 3-6C cycloalkylene; R is OH, COOH, alkoxycarbonyl,-NR1R2 or -N(R3)-(CH2)n-NR1R2; wherein R1, R2 is H, alkyl, 3-6C cycloalkyl, phenyl (optionally substituted by halo, alkoxy, alkoxycarbonyl, amino, alkylamino or dialkylamino), benzyl or saturated or unsaturated heterocyclyl having 5 or 6 members and 1-3 heteroatoms; or NR1R2 is a 5 or 6 membered heterocycle which may contain a further N, O or S heteroatom and may be alkylated; R3 is H or alkyl and n is 2-4; and alkyl moieties contain 1-4C.
wherein Me is methyl; Alk is 2-6C alkylene or 3-6C cycloalkylene; R is OH, COOH, alkoxycarbonyl,-NR1R2 or -N(R3)-(CH2)n-NR1R2; wherein R1, R2 is H, alkyl, 3-6C cycloalkyl, phenyl (optionally substituted by halo, alkoxy, alkoxycarbonyl, amino, alkylamino or dialkylamino), benzyl or saturated or unsaturated heterocyclyl having 5 or 6 members and 1-3 heteroatoms; or NR1R2 is a 5 or 6 membered heterocycle which may contain a further N, O or S heteroatom and may be alkylated; R3 is H or alkyl and n is 2-4; and alkyl moieties contain 1-4C.
2. The method of claim 1 wherein 0.01 to 50wt% of the compound in a pharmaceutically acceptable excipient is used.
3. The method of claim 2 wherein 0.1 to 20wt% of the compound in a pharmaceutically acceptable excipient is used.
4. The method of claim 2 wherein the pharmaceutically acceptable excipient is selected from the group consisting of animal oil and vegetable oil.
5. The method of claim 2 wherein the pharmaceutically acceptable excipient is selected from the group consisting of olive oil, arachis oil, castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, silicone fluid and mixtures thereof.
6. The method of claim 2 wherein the pharmaceutically acceptable excipient is selected from the group consisting of comprises polyvinyl alcohol, polyoxyethylated castor oil or methyl cellulose and mixtures thereof.
7. The method of claim 5 wherein the pharmaceutically acceptable excipient is dimethyl sulphoxide.
A method for the treatment of a disorder caused by excessive immune activity in the anterior segment, posterior segment or the vitreous body of an eye, which comprises topically administering to said eye, a cyclosporin A derivative selected from the group consisting of compounds represented by the general formulas wherein Me is methyl; Alk is 2-6C alkylene or 3-6C cycloalkylene; R is OH, COOH, alkoxycarbonyl,-NR1R2 or -N(R3)-(CH2)n - NR1R2; wherein R1, R2 is H, alkyl, 3-6C cycloalkyl, phenyl (optionally substituted by halo, alkoxy, alkoxycarbonyl, amino, alkylamino or dialkylamino), benzyl or saturated or unsaturated heterocyclyl having 5 or 6 members and 1 -3 heteroatoms; or NR1R2 is a 5 or 6 membered heterocycle which may contain a further N, O or S heteroatom and may be alkylated; R3 is H or alkyl and n is 2-4; and alkyl moieties contain 1-4C, the compound being administered in an amount sufficient to reduce said immune activity.
9. A method for enhancing or restoring lacrimal gland tearing in an eye, the method comprising administering topically to the eye, in a pharmaceutically acceptable excipient, a cyclosporin A derivative selected from the group consisting of compounds represented by the general formulas wherein Me is methyl; Alk is 2-6C alkylene or 3-6C cycloalkylene; R is OH, COOH, alkoxycarbonyl,-NR1R2 or -N(R3)-(CH2)n - NR1R2; wherein R1, R2 is H, alkyl, 3-6C cycloalkyl, phenyl (optionally substituted by halo, alkoxy, alkoxycarbonyl, amino, alkylamino or dialkylamino), benzyl or saturated or unsaturated heterocyclyl having 5 or 6 members and 1-3 heteroatonis; or NR1R2 is a 5 or 6 membered heterocycle which may contain a further N, O or S heteroatom and may be alkylated; R3 is H or alkyl and n is 2-4; and alkyl moieties contain 1-4C.
10. The method according to claim 9 wherein the compound is administered as a solution, suspension or ointment comprising 0.01 to 50 weight percent of the compound.
11. The method according to claim 10 wherein the compound is administered in an amount of 0.1 to 20 weight percent.
12. The method according to claim 9 wherein the pharmaceutically acceptable excipient is selected from the group consisting of olive oil, arachis oil, castor oil, polyoxyethylated castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, liposome, silicone fluid and mixtures thereof.
13. The method of claim 12 wherein the pharmaceutically acceptable excipient is dimethyl sulphoxide.
14. A method for treating a disorder exacerbated by deficient tear production in a patient, the method comprising administering topically to the eye, in a pharmaceutically acceptable excipient, a cyclosporin A derivative selected from the group consisting of compounds represented by the general formulas wherein Me is methyl; Alk is 2-6C alkylene or 3-6C cycloalkylene; R is OH, COOH, alkoxycarbonyl,-NR1R2 or -N(R3)-(CH2)n - NR1R2; wherein R1, R2 is H, alkyl, 3-6C cycloalkyl, phenyl (optionally substituted by halo, alkoxy, alkoxycarbonyl, amino, alkylamino or dialkylamino), benzyl or saturated or unsaturated heterocyclyl having 5 or 6 members and 1-3 heteroatoms; or NR1R2 is a 5 or 6 membered heterocycle which may contain a further N, O or S heteroatom and may be alkylated; R3 is H or alkyl and n is 2-4; and alkyl moieties contain 1-4C.
15. The method according to claim 14 wherein the compound is administered as a solution, suspension or ointment comprising 0.01 to 50 weight percent of the compound.
16. The method according to claim 15 wherein the compound is administered in an amount of 0.1 to 20 weight percent.
17. The method according to claim 14 wherein the pharmaceutically acceptable excipient is selected from the group consisting of olive oil, arachis oil, castor oil, polyoxyethylated castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, liposome, silicone fluid and mixtures thereof.
18. The method of claim 17 wherein the pharmaceutically acceptable excipient is dimethyl sulphoxide.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/290,833 | 1999-04-13 | ||
US09/290,833 US6254860B1 (en) | 1999-04-13 | 1999-04-13 | Ocular treatment using cyclosporin-A derivatives |
PCT/US2000/008877 WO2000061168A1 (en) | 1999-04-13 | 2000-04-04 | Ocular treatment using cyclosporin-a derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2369457A1 true CA2369457A1 (en) | 2000-10-19 |
CA2369457C CA2369457C (en) | 2010-08-10 |
Family
ID=23117740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2369457A Expired - Fee Related CA2369457C (en) | 1999-04-13 | 2000-04-04 | Ocular treatment using cyclosporin-a derivatives |
Country Status (11)
Country | Link |
---|---|
US (2) | US6254860B1 (en) |
EP (1) | EP1169050B1 (en) |
JP (1) | JP4711516B2 (en) |
AT (1) | ATE423566T1 (en) |
AU (1) | AU759753B2 (en) |
CA (1) | CA2369457C (en) |
DE (1) | DE60041637D1 (en) |
DK (1) | DK1169050T3 (en) |
ES (1) | ES2319853T3 (en) |
NZ (1) | NZ514105A (en) |
WO (1) | WO2000061168A1 (en) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254860B1 (en) * | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
MXPA03010632A (en) | 2001-05-21 | 2004-03-09 | Alcon Inc | Use of nf-kappa-b inhibitors to treat dry eye disorders. |
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
US7112588B2 (en) | 2001-05-21 | 2006-09-26 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
PL367287A1 (en) | 2001-05-21 | 2005-02-21 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
US6645994B1 (en) | 2001-06-01 | 2003-11-11 | Alcon, Inc. | Method of treating dry eye disorders |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
ES2428354T3 (en) | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamycin for use in the inhibition or prevention of choroidal neovascularization |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
CN102144961A (en) | 2003-09-18 | 2011-08-10 | 参天制药株式会社 | Transscleral delivery |
US20050181018A1 (en) * | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
US7083803B2 (en) * | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US20050232972A1 (en) * | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
WO2005102303A2 (en) * | 2004-04-21 | 2005-11-03 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
PT1802650E (en) * | 2004-10-01 | 2011-12-30 | Scynexis Inc | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
WO2006086750A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US20080262415A1 (en) * | 2005-07-18 | 2008-10-23 | Peyman Gholam A | Enhanced wound healing |
US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
US8329658B2 (en) * | 2005-09-30 | 2012-12-11 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
CA2625700A1 (en) | 2005-10-14 | 2007-04-26 | Allergan, Inc. | Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
NZ568694A (en) * | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
JP5528708B2 (en) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | Stable formulations and methods for preparing and using them |
US7655625B2 (en) | 2006-02-13 | 2010-02-02 | Allergan, Inc. | Methods of treating blepharospasm using cyclosporine components |
US10137083B2 (en) | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
CA2652662C (en) | 2006-05-19 | 2015-11-03 | Scynexis, Inc. | Methods for the treatment and prevention of ocular disorders |
WO2007141395A1 (en) * | 2006-06-02 | 2007-12-13 | Claude Annie Perrichon | Management of active electrons |
US7576057B2 (en) * | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
MX2009009207A (en) * | 2007-02-28 | 2010-02-12 | Aciex Therapeutics Inc | Methods and compositions for normalizing meibomian gland secretions. |
WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
CN101687013A (en) * | 2007-05-04 | 2010-03-31 | 阿勒根公司 | Use of cyclosporines in the treatment of patients with intraocular lenses |
MX2010003364A (en) | 2007-10-08 | 2010-07-06 | Lux Biosciences Inc | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors. |
BRPI0915552A2 (en) * | 2008-07-10 | 2017-06-20 | Allergan Inc | cyclosporine derivatives, their use and pharmaceutical composition |
US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
EP2376524B1 (en) * | 2008-12-31 | 2017-03-15 | Cypralis Limited | Derivatives of cyclosporin a |
SG172894A1 (en) * | 2009-01-08 | 2011-08-29 | Allergan Inc | Cyclosporine compositions for enhancing nail growth |
US20100229735A1 (en) * | 2009-03-13 | 2010-09-16 | Olaf Industries, Inc. | Coil Spring Compactor |
US20110009339A1 (en) | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
US20100279951A1 (en) * | 2009-05-01 | 2010-11-04 | Aileen Morgan | Method of treating allergic conjunctivitis with cyclosporin compositions |
WO2010138423A1 (en) * | 2009-05-27 | 2010-12-02 | Allergan, Inc. | Cyclosporin derivatives for treating inflammatory diseases and conditions |
WO2010138422A1 (en) * | 2009-05-27 | 2010-12-02 | Allergan, Inc. | Cyclosporin derivatives for enhancing the growth of hair |
MX338355B (en) | 2009-06-09 | 2016-04-13 | Aurinia Pharmaceuticals Inc | Topical drug delivery systems for ophthalmic use. |
US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
EP2498783B1 (en) | 2009-11-09 | 2018-08-22 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
JP5805773B2 (en) | 2010-10-12 | 2015-11-10 | アラーガン、インコーポレイテッドAllergan,Incorporated | Cyclosporine analog |
AU2011316690C1 (en) * | 2010-10-12 | 2017-01-19 | Allergan, Inc. | Cyclosporin analogs |
WO2013172838A1 (en) | 2012-05-17 | 2013-11-21 | Steven Yoelin | Compositions and methods for hair growth |
WO2012068515A2 (en) | 2010-11-18 | 2012-05-24 | Steven Yoelin | Compositions and methods for hair growth |
US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
MX362271B (en) | 2011-05-27 | 2019-01-10 | Allergan Inc | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof. |
EP2763649A2 (en) | 2011-10-05 | 2014-08-13 | Allergan, Inc. | Compositions for enhancing nail health |
BR112014008190A2 (en) | 2011-10-05 | 2017-04-18 | Allergan Inc | nail health enhancement compositions |
EP2779993B1 (en) | 2011-11-15 | 2018-04-04 | Allergan, Inc. | Autoclavable suspensions of cyclosporin a form 2 |
WO2013074625A1 (en) | 2011-11-15 | 2013-05-23 | Allergan, Inc. | Suspensions of cyclosporin a form 2 |
FR2988297B1 (en) * | 2012-03-22 | 2014-03-28 | Thea Lab | AQUEOUS OPHTHALMIC SOLUTION FROM CICLOSPORINE WITHOUT PRESERVATIVE |
WO2013181339A2 (en) | 2012-06-01 | 2013-12-05 | Allergan, Inc. | Cyclosporin a analogs |
EP2863892B1 (en) | 2012-06-20 | 2017-11-08 | University Of Waterloo | Mucoadhesive nanoparticle delivery system |
US9878000B2 (en) | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
US9402913B2 (en) | 2013-03-08 | 2016-08-02 | Allergan, Inc. | Cyclosporine A steroid conjugates |
WO2014152661A1 (en) * | 2013-03-14 | 2014-09-25 | Panoptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
US10149610B2 (en) * | 2014-04-25 | 2018-12-11 | Carl Zeiss Meditec, Inc. | Methods and systems for automatic detection and classification of ocular inflammation |
US9914755B2 (en) | 2015-01-08 | 2018-03-13 | Allergan, Inc. | Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized |
CA2973471A1 (en) | 2015-01-12 | 2016-07-21 | Kedalion Therapeutics, Inc. | Micro-droplet delivery device and methods |
CN107530509A (en) | 2015-04-10 | 2018-01-02 | 科达莱昂治疗公司 | Piezo dispenser with replaceable ampoule |
US9820954B2 (en) | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
KR102412086B1 (en) | 2017-01-20 | 2022-06-22 | 켄달리온 테라퓨틱스 인코포레이티드 | piezoelectric fluid dispenser |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
JP7436363B2 (en) | 2017-12-08 | 2024-02-21 | ノバルティス アーゲー | fluid delivery alignment system |
US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
WO2021026084A1 (en) | 2019-08-07 | 2021-02-11 | Aneira Pharma, Inc. | Compositions for the treatment of hair loss |
US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
JP2023523394A (en) | 2020-04-17 | 2023-06-05 | ケダリオン セラピューティックス,インコーポレイテッド | Hydrodynamically activated preservative-free dispensing system |
CN116473017B (en) * | 2023-03-22 | 2024-01-05 | 首都医科大学附属北京同仁医院 | Modeling method of mouse model based on Sjogren syndrome induced by mouse lacrimal gland |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649047A (en) | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
KR920003601B1 (en) * | 1987-09-03 | 1992-05-04 | 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 | Ocular cyclosporin composition |
FR2638089A1 (en) * | 1988-10-26 | 1990-04-27 | Sandoz Sa | NOVEL OPHTHALMIC COMPOSITIONS BASED ON CYCLOSPORINE |
FR2757520B1 (en) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | CYCLOSPORIN DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2757521B1 (en) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2757522B1 (en) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6254860B1 (en) * | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
-
1999
- 1999-04-13 US US09/290,833 patent/US6254860B1/en not_active Expired - Lifetime
-
2000
- 2000-04-04 WO PCT/US2000/008877 patent/WO2000061168A1/en active Application Filing
- 2000-04-04 EP EP00921645A patent/EP1169050B1/en not_active Expired - Lifetime
- 2000-04-04 ES ES00921645T patent/ES2319853T3/en not_active Expired - Lifetime
- 2000-04-04 NZ NZ514105A patent/NZ514105A/en not_active IP Right Cessation
- 2000-04-04 DK DK00921645T patent/DK1169050T3/en active
- 2000-04-04 DE DE60041637T patent/DE60041637D1/en not_active Expired - Lifetime
- 2000-04-04 AT AT00921645T patent/ATE423566T1/en not_active IP Right Cessation
- 2000-04-04 CA CA2369457A patent/CA2369457C/en not_active Expired - Fee Related
- 2000-04-04 JP JP2000610500A patent/JP4711516B2/en not_active Expired - Fee Related
- 2000-04-04 AU AU41935/00A patent/AU759753B2/en not_active Ceased
-
2001
- 2001-05-30 US US09/870,256 patent/US6350442B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1169050B1 (en) | 2009-02-25 |
DE60041637D1 (en) | 2009-04-09 |
WO2000061168A1 (en) | 2000-10-19 |
US6254860B1 (en) | 2001-07-03 |
CA2369457C (en) | 2010-08-10 |
NZ514105A (en) | 2005-01-28 |
DK1169050T3 (en) | 2009-04-14 |
US6350442B2 (en) | 2002-02-26 |
US20010036449A1 (en) | 2001-11-01 |
AU4193500A (en) | 2000-11-14 |
AU759753B2 (en) | 2003-05-01 |
ATE423566T1 (en) | 2009-03-15 |
ES2319853T3 (en) | 2009-05-14 |
JP2002541207A (en) | 2002-12-03 |
EP1169050A1 (en) | 2002-01-09 |
JP4711516B2 (en) | 2011-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2369457A1 (en) | Ocular treatment using cyclosporin-a derivatives | |
US5474979A (en) | Nonirritating emulsions for sensitive tissue | |
US8633162B2 (en) | Methods of providing therapeutic effects using cyclosporin components | |
US8906861B2 (en) | Pharmaceutical compositions comprising cyclosporins | |
EP0660717B1 (en) | Aminosteroids for ophthalmic use | |
JP4234907B2 (en) | Anti-inflammatory eye drops | |
US20070087962A1 (en) | Pharmaceutical compositions comprising cyclosporins | |
JPH03503159A (en) | Ophthalmic cyclosporine composition | |
CA2013167A1 (en) | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension | |
WO2006001963A1 (en) | Pharmaceutical compositions comprising cyclosporins | |
EP1242090A1 (en) | Use of h1 antagonist and a safe steroid to treat eye conditions | |
US6281224B1 (en) | Pranoprofen eyedrops containing organic amine | |
EA006937B1 (en) | Solutions containing epinastine | |
CA2648932A1 (en) | Brimonidine and timolol compositions | |
US6635654B1 (en) | Ophthalmic compositions containing loratadine | |
US5891911A (en) | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators | |
CA2463282A1 (en) | Therapeutical agent for pruritus | |
AU734137B2 (en) | Use of flunarizine for the topical treatment of glaucoma | |
WO2008024846A2 (en) | Brimonidine and timolol compositions | |
EP0375319A3 (en) | Angiotensin converting enzyme inhibitors in the treatment of glaucoma | |
JPH08231393A (en) | Allergic conjunctivitis therapeutic agent for eye local site |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160404 |